We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
+10.58%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$604M
AUM Growth
-$93M
Cap. Flow
-$139M
Cap. Flow %
-22.99%
Top 10 Hldgs %
48.64%
Holding
92
New
16
Increased
10
Reduced
22
Closed
33

Top Buys

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$29.3M
2
GMED icon
Globus Medical
GMED
+$25.7M
3
COR icon
Cencora
COR
+$21M
4
CI icon
Cigna
CI
+$16.3M
5
VTRS icon
Viatris
VTRS
+$14.8M

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$27.8M
2
CORT icon
Corcept Therapeutics
CORT
+$27.2M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$27.1M
4
LIVN icon
LivaNova
LIVN
+$26.8M
5
EMBC icon
Embecta
EMBC
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.2%
2 Industrials 6.36%
3 Miscellaneous 3.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBOT
51
BridgeBio Oncology
BBOT
$701M
$995K 0.16%
130,628
– –
TELA icon
52
TELA Bio
TELA
$31.4M
$477K 0.08%
636,300
– –
ADGM
53
Adagio Medical Holdings
ADGM
$11.3M
$455K 0.08%
698,989
-589,472
-46% -$576K
NMTC icon
54
NeuroOne Medical Technologies
NMTC
$16.1M
$252K 0.04%
82,767
-2
-0% -$8
ENVB icon
55
Enveric Biosciences
ENVB
$6.13M
$248K 0.04%
+180,000
New +$432K
MODD icon
56
Modular Medical
MODD
$28.2M
$118K 0.02%
26,190
– –
QTI
57
QT Imaging Holdings
QTI
$45.2M
$62K 0.01%
+15,236
New +$84.7K
RCKTW icon
58
Rocket Pharmaceuticals Warrant
RCKTW
$74.7K
$1.48K ﹤0.01%
400,000
– –
HUMAW
59
DELISTED
Humacyte Inc Warrant
HUMAW
$477 ﹤0.01%
49,998
– –
ABVX
60
Abivax
ABVX
$9.89B
– –
-135,800
Closed -$15.1M
BHVN icon
61
Biohaven
BHVN
$2.33B
– –
-1,163,926
Closed -$9.85M
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-194,226
Closed -$11M
CMPS
63
Compass Pathways
CMPS
$1.9B
– –
-1,506,525
Closed -$8.33M
CNC icon
64
PUT
Centene
CNC
$32B
– –
-100,000
Closed -$3.27M
CNTX icon
65
Context Therapeutics
CNTX
$35.3M
– –
-917,922
Closed -$2.4M
CORT icon
66
Corcept Therapeutics
CORT
$12.3B
– –
-674,759
Closed -$27.2M
CRNX icon
67
Crinetics Pharmaceuticals
CRNX
$9B
– –
-249,887
Closed -$9.08M
ELTX icon
68
PUT
Elicio Therapeutics
ELTX
$74.6M
– –
-11,700
Closed -$125K
EMBC icon
69
Embecta
EMBC
$286M
– –
-1,847,850
Closed -$16.3M
ENTA icon
70
Enanta Pharmaceuticals
ENTA
$396M
– –
-40,000
Closed -$505K
ERAS icon
71
Erasca
ERAS
$6.31B
– –
-5,000
Closed -$80.9K
EWTX icon
72
Edgewise Therapeutics
EWTX
$4.64B
– –
-268,986
Closed -$8.47M
FHTX icon
73
Foghorn Therapeutics
FHTX
$356M
– –
-122,889
Closed -$587K
GPCR icon
74
Structure Therapeutics
GPCR
$3.38B
– –
-209,093
Closed -$10.1M
HAE icon
75
Haemonetics
HAE
$4.73B
– –
-220,672
Closed -$12.4M
1 2
3
4

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sio Capital Management held 92 positions worth $604M, down 13% from $697M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sio Capital Management withdrew a net $139M in Q2 2026, closing 33 positions and reducing 22 holdings. Its most notable exit was Corcept Therapeutics, an estimated $27.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.

Against the trend, Sio Capital Management opened a new position in Allogene Therapeutics worth $27.7M.

  • Sio Capital Management's largest Q2 2026 buy was Allogene Therapeutics: 13,323,431 shares worth $27.7M.
  • Sio Capital Management added most to Cencora in Q2 2026, an estimated $21M increase.
  • Sio Capital Management's biggest Q2 2026 reduction was Icon, cutting an estimated $27.8M.
  • Sio Capital Management fully exited Corcept Therapeutics in Q2 2026, selling an estimated $27.2M.
  • Sio Capital Management's ten largest holdings make up 49% of its $604M portfolio in Q2 2026.
  • Sio Capital Management opened 16 new positions and closed 33 in Q2 2026.
  • Sio Capital Management's portfolio value fell 13% quarter-over-quarter to $604M.

Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.